

Activity- and Affinity- based assay of FMS tyrosine kinase: the impact of kinase phosphorylation state on the activities of various kinase inhibitory compounds.

Daisuke Kitagawa, Masaki Gouda, Masanori Nakamura, Kensaku Akita, and Koichi Yokota

Carna Biosciences, Inc., BMA 3F 1-5-5 Minatojima-Minami, Chuo, Kobe 650-0047 Japan

1. Introduction

It is well-known that the sensitivity of certain kinase inhibitors is influenced by the degree at which the kinase is phosphorylated (phosphorylation state). Although it is clear that such inhibitory compounds can discriminate between phosphorylated and nonphosphorylated protein, the biological consequences of this phosphorylation sensitivity are poorly defined. To further understand the relationship between selectivity, efficacy and safety of kinase inhibitors, we investigated effect of kinase protein phosphorylation state on various kinase inhibitors. We generated FMS (also known as CSF1R) tyrosine kinase protein to yield two differently phosphorylated batches; one was highly phosphorylated by its autophosphorylation and the other was dephosphorylated by phosphatase treatment. These two forms were then subjected to evaluation using nine kinase inhibitors in both activity-based and affinity-based assays.


A) Purified FMS protein kinase with single-site specific biotinylated. Phosphorylation Phosphorylation Phosphorylated Phosphorylated

- A) **Preparation of FMS kinase.** Cytoplasmic domain of human FMS kinase gene was cloned and expressed as N-terminal His6-tag and C-terminal biotin donor sequence fusion protein using baculovirus expression system. The FMS protein was co-expressed with biotin ligase to add the biotin to the specific donor site in Sf21 cells and purified by metal chelation column chromatography. Resulting specifically biotinylated FMS kinase was divided into two aliquots. One was autophosphorylated and the other was dephosphorylated by treatment with λ -phosphatase.
- B) **SDS-PAGE followed by CBB staining.** The band of FMS kinase was slightly shifted upward by autophosphorylation. Lane M, Molecular weight marker. Lane D, phosphatase treated (dephosphorylated) FMS kinase. Lane P, autophosphorylated (highly phosphorylated) FMS kinase.
- C) **Determination of phosphotyrosine by ELISA.** Autophosphorylated and λ -phosphatase-treated FMS kinase were immobilized on streptavidin-coated plates. Phosphorylated tyrosine was detected using anti-phospho tyrosine antibody pY20.

3. Assay platform

Phosphorylated FMS


Dephosphorylated





- A) **Activity-based assay:** FMS kinase activity was determined by ability to phosphorylate a peptide substrate. The peak ratio of phosphosubstrate to substrate (P/(P+S)) was measured by off-chip mobility shift assay (MSA) using LabChip®3000 (Caliper Life Science).
- B) **Affinity-based assay:** Europium-labeled streptavidin (StAv-Eu, FRET donor) is coupled to the FMS kinase through an interaction with its C-terminal biotin. Alexa-Fluor 647-conjugated compound (kinase tracer 178, FRET acceptor) is used as tracer. Binding of the tracer to FMS kinase results in increased TR-FRET signal between the fluorophores and the tracer.
- C) **Kinase activity of autophosphorylated and dephosphorylated FMS.** The activity of the autophosphorylated FMS was about 5-times stronger than that of dephosphorylated FMS by continuous monitoring the production of phospho-peptides. The assay was performed at the ATP concentration of 1mM.
- D) TR-FRET signal of autophosphorylated and dephosphorylated FMS. Both types of FMS kinase showed the similar TR-EPET signal


4. Results


D) Imatinib






















Soraterilib	Phos- phorylated	Dephos- phorylated	Phos- phorylated	Dephos- phorylated
IC ₅₀ (nM)	142	118	2730	9380
Standardized by Staurosporine	222	179	70	49.4
	IC ₅₀ (nM) Standardized	IC ₅₀ (nM) 142 Standardized by 222	Phos- phorylated Dephos- phorylated	Phose-phoryshed Dephose-phorylated Phose-phorylated Phose-phorylated ICs ₅₀ (nM) 142 118 2730 Standardized by 222 179 70

Activity

Affinity



		phorylated	phorylated	phorylated	phorylated
	IC ₅₀ (nM)	0.64	0.66	39.0	190
10000	Standardized by Staurosporine	1	1	1	1
	DD 470074	Activity		Affinity	
	PD173074	Phos-	Dephos-	Phos-	Dephos-



	,					
, 	Standardized by Staurosporine	144	220	111	N.D.	
0000						
ed kinase	•					

4330

A) \sim I) Potency of inhibitors toward two types of FMS tyrosine kinase was assessed by MSA and TR-FRET competition assay. ICso values were calculated from concentration vs. %Inhibition curves by fitting to a four-parameter logistic curve. Each point is an average value of at least two independent experiments.

Some compounds (GW2580, pazopanib, and sunitinib) showed different potency between phosphorylated and dephosphorylated FMS in MSA.

TR-FRET assay was insensitive to the difference of phosphorylation state of FMS.

5. Conclusions

We have successfully generated single-site specific biotinylated FMS kinase using the baculovirus expression system, that can be easily adapted for use in affinity-based assay systems.

Dephosphorylation of FMS resulted in an inactive form that possessed approximately one fifth activity of phosphorylated FMS.

Surprisingly, GW2580, pazopanib, and sunitinib showed strong inhibitory activity toward the dephosphorylated FMS compared to phosphorylated FMS, however, such a difference was not observed in TR-FRET.

Further study on the effects of phosphorylation state on potency using SPR methods will be in due course.